Celltrion and Nippon Kayaku Demonstrated Similar Effectiveness, Safety of CT-P6 (biosimilar, trastuzumab) in Retrospective Study for HER2+ Early Breast Cancer
Shots:
- The retrospective study evaluates CT-P6 vs Herceptin in 44 patients with HER2+ early breast cancer who received trastuzumab therapy, CT & pertuzumab
- The results showed similar effectiveness & safety measures, baseline characteristics were similar b/w groups, clinical CR & pCR rates were similar, 55% & 65% achieved a clinical CR & pCR rates over 66.7% & 66.7% in reference trastuzumab, AEs were similar b/w groups, 1 patient experienced an infusion-related reaction
- The results were published in The Breast. The results from an in vitro study showed that the biosimilar & trastuzumab both inhibit HER2-mediated AKT & ERK1/2 as a monothx. & combination with pertuzumab to prevent cell proliferation & colony formation
Ref: The Center For Biosimilar | Image: Celltrion
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
